Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis.

Ly-Sunnaram B, Henry C, Gandemer V, Mee FL, Burtin F, Blayau M, Cayuela JM, Oster M, Clech P, Rambeau M, Marie C, Pampin C, Edan C, Gall EL, Goasguen JE

Laboratoire d'ématologie et d'mmunologie CHU - Université de Rennes1, Avenue du Professeur Léon Bernard, Rennes, France.

We describe here a late extramedullary ovarian relapse in an 18-year-old female who was diagnosed with hypotetraploid cell acute lymphoblastic leukaemia (cALL) at the age of 6. At both occurrences of the disease cells were analyzed by morphology, immunophenotyping, cytogenetics and molecular methods. TEL/AML1 was detected by RT-PCR and FISH analysis in both events. We demonstrated, using detection of IGH/TCR rearrangements and TEL/AML1 breakpoints sequencing that the cells were clonally related. Moreover, interphasic FISH using TEL and AML1 probes showed the loss of a second TEL at the time of relapse. This observation confirms that TEL/AML1 alone is not sufficient to trigger ALL and that TEL deletion is a secondary event in leukemogenesis. To our knowledge, it is the first complete description of extramedullary ALL relapse combining all methodologies.

Published 25 July 2005 in Leuk Res, 29(9): 1089-94.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.